06.05.2024 - - Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for .
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Free Report) – Equities researchers at Wedbush decreased their FY2027 earnings per share (EPS) estimates for Rani Therapeutics in a research note issued to investors on Tuesday, February 6th. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($1.78) per share for the year, down […]
Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.
Rani Therapeutics (RANI) Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Rani Therapeutics Announces Preclinical Pharmacodynamic globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.